Great Point Partners’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Great Point Partners’s Portfolio GRCL Stock Details GRCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-579,667	Closed	-$1.67M	–	50
2023 Q3	$1.67M	Sell	579,667 -1,688,390	-74%	-$6.17M	0.3%	40
2023 Q2	$8.64M	Sell	2,268,057 -885,149	-28%	-$2.48M	1.69%	23
2023 Q1	$5.86M	Buy	3,153,206 +1,190,807	+61%	+$2.49M	1.15%	27
2022 Q4	$4.51M	Buy	1,962,399 +1,513,350	+337%	+$4.64M	0.88%	37
2022 Q3	$1.45M	Buy	+449,049	New	+$1.46M	0.35%	35

Other funds holding GRCL

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

PBPIA

Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Great Point Partners's GRCL Position: Q4 2023 in Review

Great Point Partners sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q4 2023, closing a stake of 579,667 shares — an estimated $1.67M sold.

Great Point Partners first reported a position in GRCL in Q3 2022 and held it in 5 quarters. The position peaked at $8.64M in Q2 2023. 63 funds tracked by Wall St. Rank hold GRCL as of Q4 2023.

Great Point Partners reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q4 2023 after selling out during the quarter.
Great Point Partners sold 579,667 Gracell Biotechnologies Inc. American Depositary Shares shares in Q4 2023, an estimated $1.67M.
Great Point Partners first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q3 2022 and held it in 5 quarters.
Great Point Partners's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $8.64M in Q2 2023.
63 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q4 2023.

Based on Great Point Partners's 13F filing for Q4 2023, filed 14 Feb 2024.